PriceTargets.com logo

IDEAYA Biosciences - IDYA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.40
  • Forecasted Upside: 28.85%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
$36.01 As of 12/4/2025 05:00 PM ET
▲ +1.67 (4.86%)

This chart shows the closing price for IDYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IDEAYA Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDYA

Analyst Price Target is $46.40
▲ +28.85% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $46.40, with a high forecast of $79.00 and a low forecast of $30.00. The average price target represents a 28.85% upside from the last price of $36.01.

This chart shows the closing price for IDYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 17 investment analysts is to moderate buy stock in IDEAYA Biosciences. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025Truist FinancialSet Target$59.00
11/24/2025Truist FinancialInitiated CoverageBuy$59.00
11/11/2025MizuhoBoost TargetOutperform ➝ Outperform$44.00 ➝ $46.00
10/23/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$74.00 ➝ $79.00
10/21/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$27.00 ➝ $30.00
10/21/2025New Street ResearchSet Target$30.00
10/21/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$38.00 ➝ $41.00
10/21/2025BTIG ResearchReiterated RatingBuy ➝ Buy$62.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/18/2025GuggenheimInitiated CoverageBuy ➝ Buy$50.00
9/12/2025MizuhoBoost TargetOutperform ➝ Outperform$43.00 ➝ $44.00
9/9/2025CitigroupReiterated RatingBuy ➝ Buy
9/9/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$36.00 ➝ $38.00
9/9/2025StephensReiterated RatingOverweight ➝ Overweight$45.00
9/9/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
9/8/2025OppenheimerSet TargetOutperform ➝ Outperform$36.00
9/4/2025CitigroupInitiated CoverageBuy ➝ Outperform
9/4/2025JMP SecuritiesInitiated CoverageMarket Outperform ➝ Market Outperform$41.00
9/4/2025BarclaysInitiated CoverageOverweight$40.00
9/4/2025BarclaysInitiated CoverageOverweight$40.00
9/4/2025Citizens JmpInitiated CoverageMkt Outperform$41.00
9/3/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$72.00 ➝ $74.00
7/28/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$66.00 ➝ $72.00
7/22/2025TD CowenInitiated CoverageBuy
7/10/2025The Goldman Sachs GroupUpgradeHold$25.00
7/9/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.00
6/26/2025Wells Fargo & CompanyInitiated CoverageOverweight$44.00
6/26/2025Wells Fargo & CompanyInitiated CoverageOverweight$44.00
5/22/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$63.00 ➝ $66.00
2/14/2025StephensReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00
1/15/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.00
1/13/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
12/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
12/17/2024WedbushReiterated RatingOutperform ➝ Outperform$52.00 ➝ $52.00
11/18/2024StephensInitiated CoverageOverweight$51.00
11/5/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
11/5/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$41.00 ➝ $27.00
11/4/2024WedbushReiterated RatingOutperform$52.00
10/29/2024OppenheimerReiterated RatingOutperform ➝ Outperform$53.00 ➝ $53.00
10/24/2024UBS GroupInitiated CoverageBuy$50.00
10/15/2024Cantor FitzgeraldInitiated CoverageOverweight
9/24/2024WedbushLower TargetOutperform ➝ Outperform$54.00 ➝ $52.00
9/24/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.00
9/10/2024Stifel NicolausBoost TargetBuy ➝ Buy$63.00 ➝ $68.00
8/27/2024CitigroupLower TargetBuy ➝ Buy$60.00 ➝ $58.00
8/8/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$69.00 ➝ $66.00
8/7/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.00
8/7/2024WedbushReiterated RatingOutperform ➝ Outperform$54.00 ➝ $54.00
8/7/2024OppenheimerLower TargetOutperform ➝ Outperform$60.00 ➝ $53.00
7/29/2024Lifesci CapitalUpgradeStrong-Buy
7/16/2024WedbushReiterated RatingOutperform$56.00 ➝ $54.00
7/12/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$65.00 ➝ $69.00
7/11/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$53.00 ➝ $61.00
7/9/2024BTIG ResearchBoost TargetBuy ➝ Buy$55.00 ➝ $62.00
7/8/2024OppenheimerBoost TargetOutperform ➝ Outperform$53.00 ➝ $60.00
7/8/2024Stifel NicolausReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
7/8/2024WedbushReiterated RatingOutperform$52.00 ➝ $56.00
7/8/2024MizuhoInitiated CoverageOutperform$50.00
6/4/2024Stifel NicolausBoost TargetBuy ➝ Buy$55.00 ➝ $63.00
5/13/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$53.00 ➝ $46.00
5/8/2024WedbushReiterated RatingOutperform ➝ Outperform$52.00
3/21/2024CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $60.00
3/8/2024BTIG ResearchInitiated CoverageBuy$55.00
2/23/2024Leerink PartnrsReiterated RatingOutperform
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.00 ➝ $57.00
2/22/2024Capital One FinancialReiterated RatingOverweight
2/21/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$43.00 ➝ $53.00
1/25/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$36.00 ➝ $53.00
1/10/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$36.00 ➝ $43.00
12/6/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$36.00
11/30/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$35.00 ➝ $41.00
11/8/2023GuggenheimLower TargetBuy ➝ Buy$48.00 ➝ $44.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$43.00
10/24/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$32.00 ➝ $36.00
10/11/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$32.00
9/12/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$31.00 ➝ $37.00
9/12/2023WedbushBoost TargetOutperform ➝ Outperform$40.00 ➝ $43.00
8/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$28.00 ➝ $32.00
8/11/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$30.00 ➝ $32.00
8/11/2023WedbushBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
8/11/2023OppenheimerBoost TargetOutperform ➝ Outperform$30.00 ➝ $35.00
8/8/2023Leerink PartnrsReiterated RatingOutperform
8/8/2023Leerink PartnersInitiated CoverageOutperform$33.00
8/8/2023SVB SecuritiesInitiated CoverageOutperform$33.00
5/24/2023The Goldman Sachs GroupInitiated CoverageBuy$32.00
4/24/2023WedbushBoost Target$30.00 ➝ $35.00
4/24/2023OppenheimerBoost Target$26.00 ➝ $30.00
4/24/2023GuggenheimBoost Target$32.00 ➝ $40.00
4/24/2023Stifel NicolausUpgradeHold ➝ Buy$18.00 ➝ $24.00
3/23/2023Berenberg BankInitiated CoverageBuy$26.00
3/17/2023CitigroupBoost Target$26.00 ➝ $29.00
3/8/2023GuggenheimReiterated RatingBuy$32.00
3/8/2023Royal Bank Of CanadaReiterated RatingOutperform$25.00
2/28/2023Royal Bank Of CanadaInitiated CoverageOutperform$25.00
1/23/2023OppenheimerBoost Target$22.00 ➝ $26.00
12/28/2022Capital One FinancialInitiated CoverageOverweight$29.00
12/14/2022WedbushBoost Target$30.00
11/18/2022Robert W. BairdBoost TargetOutperform$18.00 ➝ $24.00
10/27/2022CitigroupInitiated CoverageBuy$26.00
9/13/2022GuggenheimBoost TargetBuy$20.00 ➝ $32.00
9/6/2022OppenheimerBoost Target$22.00
8/16/2022Robert W. BairdLower TargetOutperform$26.00 ➝ $18.00
8/16/2022OppenheimerLower TargetOutperform$25.00 ➝ $20.00
8/15/2022Stifel NicolausDowngradeBuy ➝ Hold$16.00 ➝ $13.00
7/18/2022OppenheimerReiterated RatingOutperform$25.00
5/17/2022Roth CapitalBoost Target$42.00 ➝ $46.00
3/16/2022WedbushReiterated RatingOutperform$34.00
3/10/2022Stifel NicolausUpgradeHold ➝ Buy$27.00 ➝ $20.00
12/8/2021Roth CapitalBoost TargetBuy ➝ Buy$38.00 ➝ $42.00
9/22/2021Stifel NicolausInitiated CoverageHold$27.00
8/11/2021HC WainwrightLower TargetBuy$34.00 ➝ $30.00
5/11/2021HC WainwrightLower TargetBuy$35.00 ➝ $34.00
4/22/2021Roth CapitalBoost TargetPositive ➝ Buy$31.00 ➝ $38.00
4/19/2021HC WainwrightBoost TargetPositive ➝ Buy$29.00 ➝ $35.00
4/16/2021Roth CapitalBoost Target$23.00 ➝ $31.00
4/16/2021JPMorgan Chase & Co.Boost TargetOverweight$28.00 ➝ $34.00
3/24/2021CitigroupBoost Target$20.00 ➝ $33.00
3/15/2021WedbushBoost TargetOutperform$25.00 ➝ $32.00
3/11/2021GuggenheimInitiated CoverageBuy$32.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 22 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 29 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 8 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 22 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 15 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 9 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 18 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 18 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

IDEAYA Biosciences logo
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $36.01
Low: $34.00
High: $36.61

50 Day Range

MA: $30.75
Low: $26.24
High: $36.01

52 Week Range

Now: $36.01
Low: $13.45
High: $36.61

Volume

1,474,616 shs

Average Volume

845,148 shs

Market Capitalization

$3.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Frequently Asked Questions

What sell-side analysts currently cover shares of IDEAYA Biosciences?

The following Wall Street research analysts have issued reports on IDEAYA Biosciences in the last year: Barclays PLC, BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, JMP Securities, JPMorgan Chase & Co., Mizuho, New Street Research, Oppenheimer Holdings, Inc., Royal Bank Of Canada, Stephens, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, Wall Street Zen, Wedbush, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for IDYA.

What is the current price target for IDEAYA Biosciences?

0 Wall Street analysts have set twelve-month price targets for IDEAYA Biosciences in the last year. Their average twelve-month price target is $46.40, suggesting a possible upside of 28.9%. JPMorgan Chase & Co. has the highest price target set, predicting IDYA will reach $79.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $30.00 for IDEAYA Biosciences in the next year.
View the latest price targets for IDYA.

What is the current consensus analyst rating for IDEAYA Biosciences?

IDEAYA Biosciences currently has 1 sell rating, 1 hold rating and 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IDYA.

What other companies compete with IDEAYA Biosciences?

Other companies that are similar to IDEAYA Biosciences include Viatris, Dr. Reddy's Laboratories, Elanco Animal Health, Avidity Biosciences and Qiagen. Learn More about companies similar to IDEAYA Biosciences.

How do I contact IDEAYA Biosciences' investor relations team?

IDEAYA Biosciences' physical mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 443-6209 and its investor relations email address is [email protected]. The official website for IDEAYA Biosciences is www.ideayabio.com. Learn More about contacing IDEAYA Biosciences investor relations.